Literature DB >> 31563911

Uremic Toxins and their Relation to Dialysis Efficacy.

William R Clark1, Nader Laal Dehghani2, Vivek Narsimhan2, Claudio Ronco3,4.   

Abstract

Toxin retention is felt to be a major contributor to the development of uremia in patients with advanced chronic kidney disease and end-stage renal disease (ESRD). Uremic retention compounds are classically divided into 3 categories: small solutes, middle molecules, and protein-bound toxins. Compounds comprising the first category, for which the upper molecular weight limit is generally considered to be 500 Da, possess a high degree of water solubility and minimal or absent protein binding. The second category of middle molecules has largely evolved now to be synonymous with peptides and proteins that accumulate in uremia. Although not precisely defined, low-molecular weight proteins as a class have a molecular weight spectrum ranging from approximately 500 to 60,000 daltons. The final category of uremic retention compounds is protein-bound uremic toxins (PBUTs). As opposed to the above small, highly water-soluble toxins, which are largely by-products of protein metabolism, PBUTs have diverse origins and possess chemical characteristics that preclude the possibility of circulation in an unbound form despite being of low molecular weight. This review is the first in a series of papers designed to provide the current state of the art for extracorporeal treatment of ESRD. Subsequent papers in this series will address membranes, mass transfer mechanisms, and future directions. For small solutes and middle molecules, particular emphasis is placed on the important clinical trials that comprise the evidence base regarding the influence of dialytic solute removal on outcome. Because such trials do not exist for PBUTs, the discussion here is instead focused on solute characteristics and renal elimination mechanisms.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Middle molecule; Protein binding; Small solute; Toxin; Urea; Uremia; β2-Microglobulin

Mesh:

Substances:

Year:  2019        PMID: 31563911     DOI: 10.1159/000502331

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  15 in total

Review 1.  The membrane perspective of uraemic toxins: which ones should, or can, be removed?

Authors:  Sudhir K Bowry; Peter Kotanko; Rainer Himmele; Xia Tao; Michael Anger
Journal:  Clin Kidney J       Date:  2021-12-27

2.  Serum concentrations of free indoxyl and p-cresyl sulfate are associated with mineral metabolism variables and cardiovascular risk in hemodialysis patients.

Authors:  Teresa Arcidiacono; Lorenza Macrina; Simone Premaschi; Arianna Bologna; Giulia Magni; Nadia Foligno; Monica Avino; Cristina Belloni; Nicola Palmieri; Ferruccio Conte; Sergio Bisegna; Marco Simonini; Giorgio Slaviero; Massimo Locatelli; Giuseppe Vezzoli
Journal:  J Nephrol       Date:  2022-02-17       Impact factor: 4.393

Review 3.  Mass Transport in High-Flux Hemodialysis: Application of Engineering Principles to Clinical Prescription.

Authors:  Farzad Mohajerani; William R Clark; Claudio Ronco; Vivek Narsimhan
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-11       Impact factor: 10.614

Review 4.  Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins.

Authors:  Chia-Ter Chao; Shih-Hua Lin
Journal:  Toxins (Basel)       Date:  2020-12-21       Impact factor: 4.546

5.  Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients.

Authors:  Adamasco Cupisti; Piergiorgio Bolasco; Claudia D'Alessandro; Domenico Giannese; Alice Sabatino; Enrico Fiaccadori
Journal:  Toxins (Basel)       Date:  2021-04-19       Impact factor: 4.546

6.  Exploring the experiences and perceptions of haemodialysis patients observing Ramadan fasting: a qualitative study.

Authors:  Nurul Iman Hafizah Adanan; Wan Ahmad Hafiz Wan Md Adnan; Pramod Khosla; Tilakavati Karupaiah; Zulfitri Azuan Mat Daud
Journal:  BMC Nephrol       Date:  2021-02-02       Impact factor: 2.388

7.  End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression.

Authors:  Ruijing Zhang; Jason Saredy; Ying Shao; Tian Yao; Lu Liu; Fatma Saaoud; William Y Yang; Yu Sun; Candice Johnson; Charles Drummer; Hangfei Fu; Yifan Lu; Keman Xu; Ming Liu; Jirong Wang; Elizabeth Cutler; Daohai Yu; Xiaohua Jiang; Yafeng Li; Rongshan Li; Lihua Wang; Eric T Choi; Hong Wang; Xiaofeng Yang
Journal:  Redox Biol       Date:  2020-02-20       Impact factor: 11.799

8.  A Novel Uremic Score Reflecting Accumulation of Specific Uremic Toxins More Precisely Predicts One-Year Mortality after Hemodialysis Commencement: A Retrospective Cohort Study.

Authors:  Yohei Arai; Shingo Shioji; Hiroyuki Tanaka; Daisuke Katagiri; Fumihiko Hinoshita
Journal:  Toxins (Basel)       Date:  2020-10-01       Impact factor: 4.546

Review 9.  Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives.

Authors:  Stefania Magnani; Mauro Atti
Journal:  Toxins (Basel)       Date:  2021-03-30       Impact factor: 4.546

10.  Optical Method and Biochemical Source for the Assessment of the Middle-Molecule Uremic Toxin β2-Microglobulin in Spent Dialysate.

Authors:  Joosep Paats; Annika Adoberg; Jürgen Arund; Ivo Fridolin; Kai Lauri; Liisi Leis; Merike Luman; Risto Tanner
Journal:  Toxins (Basel)       Date:  2021-03-31       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.